课题基金 / 基金详情

OPEN LABEL LJP 394 FOR SLE W/ DNA AB

OPEN LABEL LJP 394 FOR SLE W/ DNA AB
开放标签 LJP 394 用于 SLE 带 DNA AB
批准号：
6265443
负责人：
K LEA SEWELL
金额：
$2.98万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265443
关键词：
antiantibody clinical research connective tissue disorder chemotherapy drug adverse effect drug screening /evaluation human subject human therapy evaluation oligonucleotides systemic lupus erythematosus

项目摘要

项目成果

K LEA SEWELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To determine the long-term safety and efficacy of LJP 394 in patients with a prior history of active lupus renal disease, who were producing anti-ds DNA antibodies upon enrollment 18 months ago for the initial LJP 394 trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REPEATED DOSES OF LJP 394 IN PATIENTS WITH SLE NEPHRITIS
OPEN LABEL LJP 394 FOR SLE W/ HIGH DNA AB
LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
DOSE RANGING TRIAL OF LJP 394 IN PATIENTS W/ SLE
海外基金